ProShare Advisors
AMLX icon

ProShare Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

ProShare Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Sell
15,685
-2,469
-14% -$38.2K ﹤0.01% 1459
2026
Q1 		$252K Sell
18,154
-2,914
-14% -$41K ﹤0.01% 1430
2025
Q4 		$255K Buy
21,068
+6,030
+40% +$81.9K ﹤0.01% 1559
2025
Q3 		$204K Sell
15,038
-2,513
-14% -$23.7K ﹤0.01% 1688
2025
Q2 		$113K Buy
+17,551
New +$85.4K ﹤0.01% 1856
2024
Q3 		– Sell
-11,000
Closed -$20.9K – 2067
2024
Q2 		$20.9K Sell
11,000
-2,874
-21% -$5.57K ﹤0.01% 1808
2024
Q1 		$39.4K Buy
13,874
+1,153
+9% +$15.1K ﹤0.01% 1932
2023
Q4 		$187K Buy
12,721
+1,715
+16% +$26.3K ﹤0.01% 1656
2023
Q3 		$202K Buy
11,006
+54
+0.5% +$1.14K ﹤0.01% 1460
2023
Q2 		$236K Buy
10,952
+424
+4% +$11.5K ﹤0.01% 1434
2023
Q1 		$309K Sell
10,528
-1,440
-12% -$50K ﹤0.01% 1199
2022
Q4 		$442K Buy
+11,968
New +$425K ﹤0.01% 1020

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ProShare Advisors's AMLX Position: Q2 2026 in Review

ProShare Advisors reduced its Amylyx Pharmaceuticals (AMLX) stake by 14% in Q2 2026, selling an estimated $38.2K and leaving 15,685 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

ProShare Advisors first reported a position in AMLX in Q4 2022 and has held it in 12 quarters since. The position peaked at $442K in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • ProShare Advisors held 15,685 shares of Amylyx Pharmaceuticals worth $282K as of Q2 2026.
  • ProShare Advisors sold 2,469 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $38.2K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1459 holding.
  • ProShare Advisors first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • ProShare Advisors's Amylyx Pharmaceuticals position peaked at $442K in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.